Grant: $52,949 - National Institutes of Health - Sep. 2, 2009
No votes have been cast for this award yet
Award Description: The goals of this supplement are to increase our productivity and reduce environmental waste. This application is a request for an administrative supplement from the American Recovery and Reinvestment Act of 2009 for our parent grant, CA60651, 'Mouse Models to Study Gonadal Tumor Development . Our parent grant has been funded continuously by NCI since 1993 and has allowed us to study the pathogenesis of ovarian cancer at the molecular level in vivo. Ovarian cancer is the leading cause of death due to gynecologic malignancy and accounts for nearly one-fourth of all female deaths from cancer. With the support of this grant, we have generated important mammalian models to study ovarian, testicular, and adrenal cancer development and defined major growth regulatory pathways involved in gonadal physiology. Over this funding period, Martin M. Matzuk, M.D., Ph.D. (the Principal Investigator) and his laboratory have been highly productive and leaders in the identification and characterization of the roles of growth factors and endocrine signaling in the gonads. We were the first to discover that a secreted growth factor (inhibin) could function as a tumor suppressor in vivo. Our work has resulted in 86 papers published to date with the support of our NCI-funded grant. We have made significant progress on the Specific Aims of the current grant period and have already published 17 papers. In this ARRA application, we are requesting supplemental funds to purchase a necessary piece of equipment, the FluorChem Q Quantitative Western Blot Imaging System, manufactured by Alpha Innotech, which is headquartered in San Leandro, California. These supplemental funds to purchase the FluorChem Q Quantitative Western Blot Imaging System satisfy the goals of the American Recovery and Reinvestment Act as follows: 1) They will accelerate the tempo of scientific cancer research in the P.I.’s laboratory in completing the Specific Aims including publication of key papers in the area of ovarian cancer; 2) They will accelerate the tempo of scientific research in anticipation of submitting a renewal application for extension of these studies beyond 2011; 3) They will reduce long term costs associated with current Western blot strategies; and 4) They will minimize the generation of environmentally hazardous waste as requested by the Environmental Protection Agency (EPA) and the Texas Commission on Environmental Quality (TCEQ). These studies will not only accelerate our research program but will also accelerate the US economy since the equipment is supplied to us by Alpha Innotech, a United States manufacturer established in 1992 in San Leandro, California. Our studies on ovarian cancer using this equipment are directly relevant to the mission of the National Cancer Institute by allowing us to understanding the pathophysiology of ovarian cancer. Our work is crucial to improving the health and quality-of-life of women around the world and will ultimately improve the diagnosis and treatment of ovarian cancer. Ovarian cancer is the 5th leading cause of death due to cancer in women. Consistent with the goals of the ARRA, this supplement will be used to purchase a major piece of equipment to speed the tempo to complete the Specific Aims of our parent grant that has been funded since 1993. Long term, this equipment will increase the quality of our research, reduce supply costs, and reduce the generation of environmentally hazardous laboratory materials associated with alternative Western blot strategies.
Project Description: As defined in the Award Description field
Jobs Summary: N/A (Total jobs reported: 0)
Project Status: Not Started
This award's data was last updated on Sep. 2, 2009. Help expand these official descriptions using the wiki below.